Page 97 - Read Online

Page 296 Schwarzenbach et al. Cancer Drug Resist 2019;2:271-96 I http://dx.doi.org/10.20517/cdr.2019.010

166. Xu M, Xiao J, Chen M, Yuan L, Li J, et al. MiR1495p promotes chemotherapeutic resistance in ovarian cancer via the inactivation of the
Hippo signaling pathway. Int J Oncol 2018;52:815-27.
167. He J, Yu JJ, Xu Q, Wang L, Zheng JZ, et al. Downregulation of ATG14 by EGR1-MIR152 sensitizes ovarian cancer cells to cisplatin-
induced apoptosis by inhibiting cyto-protective autophagy. Autophagy 2015;11:373-84.
168. Xiang Y, Ma N, Wang D, Zhang Y, Zhou J, et al. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by
targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine. Oncogene 2014;33:378-86.
169. Sun KX, Jiao JW, Chen S, Liu BL, Zhao Y. MicroRNA-186 induces sensitivity of ovarian cancer cells to paclitaxel and cisplatin by
targeting ABCB1. J Ovarian Res 2015;8:80.
170. Zhu X, Shen H, Yin X, Long L, Xie C, et al. MiR-186 regulation of Twist1 and ovarian cancer sensitivity to cisplatin. Oncogene
2016;35:323-32.
171. Cui Y, Wu F, Tian D, Wang T, Lu T, et al. MiR-199a-3p enhances cisplatin sensitivity of ovarian cancer cells by targeting ITGB8. Oncol
Rep 2018;39:1649-57.
172. Wang Z, Ting Z, Li Y, Chen G, Lu Y, et al. MicroRNA-199a is able to reverse cisplatin resistance in human ovarian cancer cells through
the inhibition of mammalian target of rapamycin. Oncol Lett 2013;6:789-94.
173. Liu MX, Siu MK, Liu SS, Yam JW, Ngan HY, et al. Epigenetic silencing of microRNA-199b-5p is associated with acquired
chemoresistance via activation of JAG1-Notch1 signaling in ovarian cancer. Oncotarget 2014;5:944-58.
174. Zhu X, Shen H, Yin X, Long L, Chen X, et al. IL-6R/STAT3/miR-204 feedback loop contributes to cisplatin resistance of epithelial
ovarian cancer cells. Oncotarget 2017;8:39154-66.
175. Lin M, Xia B, Qin L, Chen H, Lou G. S100A7 regulates ovarian cancer cell metastasis and chemoresistance through MAPK signaling
and is targeted by miR-330-5p. DNA Cell Biol 2018;37:491-500.
176. Liu R, Guo H, Lu S. MiR-335-5p restores cisplatin sensitivity in ovarian cancer cells through targeting BCL2L2. Cancer Med
2018;7:4598-609.
177. Cao L, Wan Q, Li F, Tang CE. MiR-363 inhibits cisplatin chemoresistance of epithelial ovarian cancer by regulating snail-induced
epithelial-mesenchymal transition. BMB Rep 2018;51:456-61.
178. Ye G, Fu G, Cui S, Zhao S, Bernaudo S, et al. MicroRNA 376c enhances ovarian cancer cell survival by targeting activin receptor-like
kinase 7: implications for chemoresistance. J Cell Sci 2011;124:359-68.
179. Zou J, Liu L, Wang Q, Yin F, Yang Z, et al. Downregulation of miR-429 contributes to the development of drug resistance in epithelial
ovarian cancer by targeting ZEB1. Am J Transl Res 2017;9:1357-68.
180. Wu H, Xiao Z, Zhang H, Wang K, Liu W, et al. MiR-489 modulates cisplatin resistance in human ovarian cancer cells by targeting Akt3.
Anticancer Drugs 2014;25:799-809.
181. Tian J, Xu YY, Li L, Hao Q. MiR-490-3p sensitizes ovarian cancer cells to cisplatin by directly targeting ABCC2. Am J Transl Res
2017;9:1127-38.
182. Xu S, Fu GB, Tao Z, OuYang J, Kong F, et al. MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/
P70S6K1. Oncotarget 2015;6:26457-71.
183. van Jaarsveld MT, van Kuijk PF, Boersma AW, Helleman J, van IWF, et al. MiR-634 restores drug sensitivity in resistant ovarian cancer
cells by targeting the Ras-MAPK pathway. Mol Cancer 2015;14:196.
184. Qin X, Sun L, Wang J. Restoration of microRNA-708 sensitizes ovarian cancer cells to cisplatin via IGF2BP1/Akt pathway. Cell Biol Int
2017;41:1110-8.
185. Wu DD, Li XS, Meng XN, Yan J, Zong ZH. MicroRNA-873 mediates multidrug resistance in ovarian cancer cells by targeting ABCB1.
Tumour Biol 2016;37:10499-506.
186. Brozovic A, Duran GE, Wang YC, Francisco EB, Sikic BI. The miR-200 family differentially regulates sensitivity to paclitaxel and
carboplatin in human ovarian carcinoma OVCAR-3 and MES-OV cells. Mol Oncol 2015;9:1678-93.
187. Vecchione A, Belletti B, Lovat F, Volinia S, Chiappetta G, et al. A microRNA signature defines chemoresistance in ovarian cancer
through modulation of angiogenesis. Proc Natl Acad Sci U S A 2013;110:9845-50.